Comparison · NCT02947087-sae
Prolastin-C vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Prolastin-C vs Placebo: serious adverse events. Trial comparisons, record NCT02947087-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02947087-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.759 | 0.579 | 0.878 | wilson | |
| Risk in group 2 | 0.571 | 0.326 | 0.786 | wilson | |
| Risk difference, group 1 minus group 2 | 0.187 | -0.0928 | 0.46 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.807 | 2.18 | log | |
| Odds ratio, group 1 over group 2 | 2.36 | 0.606 | 9.16 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Prolastin-C than on Placebo | 5.34 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Prolastin-C | Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.~Prolastin-C: Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation | 22 | 29 | EG000 |
| Group 2 | Placebo | Subjects will be given Saline weekly for 4 weeks.~Placebo: Patients will receive saline on day 0, 7, 14, and 21 days of transplantation | 8 | 14 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
- NCT number
- NCT02947087
- Phases
- PHASE1, PHASE2
- Conditions
- Chronic Pancreatitis
- Interventions
- Prolastin-C, Placebo
- Lead sponsor
- Medical University of South Carolina
- Results first posted
- 2023-05-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02947087?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02947087-sae